159 related articles for article (PubMed ID: 21306626)
1. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
[TBL] [Abstract][Full Text] [Related]
2. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
3. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
4. Item response analysis of the Positive and Negative Syndrome Scale.
Santor DA; Ascher-Svanum H; Lindenmayer JP; Obenchain RL
BMC Psychiatry; 2007 Nov; 7():66. PubMed ID: 18005449
[TBL] [Abstract][Full Text] [Related]
5. An excitement subscale of the Positive and Negative Syndrome Scale.
Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
[TBL] [Abstract][Full Text] [Related]
6. The heterogeneity of antipsychotic response in the treatment of schizophrenia.
Case M; Stauffer VL; Ascher-Svanum H; Conley R; Kapur S; Kane JM; Kollack-Walker S; Jacob J; Kinon BJ
Psychol Med; 2011 Jun; 41(6):1291-300. PubMed ID: 20925971
[TBL] [Abstract][Full Text] [Related]
7. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
9. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
11. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
12. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
13. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
14. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369
[TBL] [Abstract][Full Text] [Related]
15. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
Khan A; Yavorsky WC; Liechti S; DiClemente G; Rothman B; Opler M; DeFries A; Jovic S
J Clin Psychopharmacol; 2013 Feb; 33(1):109-17. PubMed ID: 23277234
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
18. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
[TBL] [Abstract][Full Text] [Related]
19. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
20. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
